Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin [fluorouracil/folinic acid] (G-FLIE) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exocrine Pancreas.

Trial Profile

Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin [fluorouracil/folinic acid] (G-FLIE) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exocrine Pancreas.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top